The Women’s Oncology Panel is designed for comprehensive laboratory evaluation in cases of clinical suspicion, medical follow-up, or physician recommendation.
The panel combines general blood testing, inflammatory markers, extended biochemistry, and tumor markers commonly used in women.
These laboratory results do not establish a diagnosis on their own and must be interpreted within the context of a full clinical assessment.

What does the panel include?

The panel includes:

• CBC + Differential – complete blood count with white cell differential
• CRP – inflammatory marker
• Complete Biochemistry – liver function, kidney function, electrolytes, and metabolic parameters
• Urea – kidney function indicator
• CA 125 – marker commonly used in the evaluation of ovarian-related conditions
• CA 15-3 – marker primarily used in monitoring breast conditions
• CEA – general tumor marker, often associated with gastrointestinal conditions
• AFP (Alpha-Fetoprotein) – marker mainly associated with liver conditions
• CA 19-9 – marker used in evaluation of pancreatic and gastrointestinal conditions
• CA 72-4 – marker associated with gastrointestinal conditions

The combination provides a broad laboratory overview across multiple systems.

Who is this panel suitable for?

• Unexplained general symptoms
• Unintentional weight loss
• Follow-up after an oncologic diagnosis
• Monitoring after treatment
• Evaluation based on physician recommendation
• Situations requiring extended laboratory assessment

This panel is not a routine screening test and does not replace imaging or other targeted diagnostic procedures.

What is the advantage of a panel over a single test?

A single tumor marker does not provide a complete clinical picture.
Elevated values may also occur in benign or inflammatory conditions.

A combined panel allows:

• Detection of abnormalities across multiple systems
• Supportive evaluation in cases of clinical suspicion
• Monitoring of trends over time
• Cross-analysis of different laboratory markers

How is the test performed?

• A venous blood sample is collected
• Fasting for approximately 8 hours is recommended for biochemical testing
• Patients should inform their physician about ongoing medications
• No additional preparation is generally required

How are the results interpreted?

Tumor markers may be elevated in inflammatory or benign conditions.
Abnormal results do not confirm the presence of malignancy.
Interpretation is performed in the context of medical history, physical examination, and imaging studies when required.

⚠️ Interpretation of results requires medical consultation.
Laboratory findings should not be interpreted without full clinical evaluation.

Possible complementary investigations

• Gynecologic ultrasound
• Mammography or additional breast imaging
• CT or MRI when clinically indicated
• Hormonal testing
• Biopsy when recommended

Further medical evaluation

If abnormal values are detected, further assessment is determined according to the clinical context.

Repeat testing may be recommended to evaluate trends over time.

Consultation may be recommended with:

• Primary care physician
• Gynecologist
• Breast specialist
• Oncologist

Additional Professional Information

All tests are performed in a clinical laboratory operating in accordance with established professional standards and internal quality control procedures.
Results are issued in accordance with validated laboratory protocols.

Interpretation of findings is conducted within the framework of clinical evaluation by the treating physician.